Thrivent Financial for Lutherans Invests $3.80 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Thrivent Financial for Lutherans bought a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the third quarter, Holdings Channel.com reports. The fund bought 190,205 shares of the biotechnology company’s stock, valued at approximately $3,802,000.

Other large investors have also added to or reduced their stakes in the company. Mutual of America Capital Management LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at $701,000. Natixis Advisors LLC acquired a new position in ADMA Biologics in the 3rd quarter valued at about $345,000. Oppenheimer & Co. Inc. raised its holdings in ADMA Biologics by 85.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 94,938 shares of the biotechnology company’s stock valued at $1,898,000 after acquiring an additional 43,836 shares during the period. Aigen Investment Management LP bought a new position in ADMA Biologics in the 3rd quarter valued at about $583,000. Finally, Entropy Technologies LP acquired a new stake in ADMA Biologics during the third quarter worth approximately $757,000. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Finally, HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

Insider Buying and Selling

In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of ADMA Biologics stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $17.27, for a total value of $2,363,589.47. Following the transaction, the director now owns 467,305 shares in the company, valued at $8,070,357.35. The trade was a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 185,011 shares of company stock valued at $3,255,204 over the last quarter. 3.70% of the stock is owned by company insiders.

ADMA Biologics Stock Down 0.6 %

NASDAQ ADMA opened at $21.18 on Monday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $5.01 billion, a price-to-earnings ratio of 75.64 and a beta of 0.64. The company has a 50 day moving average of $18.86 and a 200-day moving average of $14.89. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm earned $0.01 EPS. On average, equities research analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.